结核性胸膜炎胸腔注入尿激酶或激素疗效比较的Meta分析-东南大学学报医学版

结核性胸膜炎胸腔注入尿激酶或激素疗效比较的Meta分析

单位：1. 川北医学院附属医院心内科, 四川南充 637000;
2. 西南石油大学理学院, 四川成都 610500;
3. 都江堰市中医医院内科, 四川成都 611830

分类号：R561.1,R561.3

出版年·卷·期（页码）：2015·34·第三期（369-372）

摘要：

目的:比较胸腔内注射尿激酶或糖皮质激素治疗结核性胸膜炎的疗效性和安全性.方法: 计算机检索Medline、Embase、Cochrane-library、Web of science、中国生物医学文献数据库、中文科技期刊数据库、中国知网、万方医学网数据库,并辅以手工检索从建库起至2014年11月关于胸腔内注入尿激酶或激素治疗结核性胸膜炎疗效比较的随机对照研究文献,采用RevMan 5.2.3软件行数据分析.结果:纳入5项研究,Meta分析显示,尿激酶组和激素组的胸水完全吸收时间 (RR=0.48,P=0.22)、胸膜增厚发生率(RR=0.67,P=0.06) 及不良反应 (RR=1.17,P=0.70)差异无统计学意义;胸膜厚度有明显异质性(I²=91%),不予Meta合并.结论:胸腔内注入尿激酶或激素治疗结核性胸膜炎疗效和安全性比较无显著差异.

Objective: To evaluate the efficacy and safety of intrapleural urokinase or glucocorticoid in treatment of tuberculous pleural effusion. Methods:All randomized controlled trials,which studied comparison of effects between intrapleural urokinase or glusocorticoid for tuberculous pleural effusion,were searched from Medline, Embase,Cochrane-library,Web of science,Chinese Biomedical Literature Database,Chinese National Knowledge Infrastructure,Chinese Scientific Journal Database,Wanfang Med Online Database up to November 2014. All were searched by manual and computer retrieval. RevMan 5.2.3 was used for data analysis. Results: Five literatures were included in this study. No statistical difference was found between urokinase group and glucocorticoid group on hydrothorax absorption days (RR=0.48,P=0.22), the incidence of pleural thickening(RR=0.67,P=0.06) and adverse reaction(RR=1.17,P=0.70).But due to significant heterogeneity, the description rather than Meta-analysis was managed on index of thickness of pleura (I²=91%).Conclusion: There is no significant difference between intrapleural urokinase and glucocorticoid on effects and safety in the treatment of tuberculous pleural effusion.

参考文献：

[1] ORDONEZ A A,MAIGA M,GUPTA S,et al.Novel adjunctive therapies for the treatment of tuberculosis[J].Curr Mol Med,2014,14(3):385-395.
[2] JEON D.Tuberculous pleurisy:an update[J].Tuberc Respir Dis (Seoul),2014,76(4):153-159.
[3] LIGHT R W.Update on tuberculous pleural effusion[J].Respirology,2010,15(3):451-458.
[4] 王小路,梅敏,钱小军.地塞米松与尿激酶联合应用注入胸腔治疗大鼠结核性胸膜炎的实验研究[J].实用临床医学,2013,14(8):12-13.
[5] VILLENA GARRIDO V,CASES VIEDMA E,FERNNDEZ VILLAR A,et al.Recommendations of diagnosis and treatment of pleural effusion.Update [J].Arch Bronconeumol,2014,50(6):235-249.
[6] 缪龙生,曹红勇,马宁,等.腹腔镜完全腹膜外间隙与开放式无张力疝修补术治疗成人腹股沟疝临床疗效的Meta分析[J].现代医学,2014,42(6):593-600.
[7] 王雪飞,洪丽欣.心理干预对卵巢癌手术患者焦虑抑郁症状影响的Meta分析[J].现代医学,2014,42(3):248-252.
[8] 易春峰,李元红,江洪.丹红注射液联合低分子肝素治疗不稳定型心绞痛的Meta分析[J].现代医学,2013,41(9):620-626.
[9] THORLUND K,IMBERGER G,JOHNSTON B C,et al.Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses[J].PLoS One,2012,7(7):e39471.
[10] 胡锦全,王云甫,孙延鹏,等.米托蒽醌治疗多发性硬化有效性和安全性的Meta分析[J].现代医学,2014,42(5):482-486.
[11] 李群芝,刘艳.尿激酶联合地塞米松胸腔内注射治疗结核性胸膜炎的疗效观察[J].黑龙江医药,2014,(3):606-607.
[12] 李广德,程小星.胸腔注射尿激酶联合地塞米松治疗结核性胸膜炎的临床效果[J].中国医药导报,2013,10(15):104-105.
[13] 汪夙兴,欧阳海峰.尿激酶、地塞米松预防及治疗结核性胸膜炎胸膜肥厚和胸膜粘连的研究[J].实用临床医学, 2013,14(2):33-34.
[14] 蒋奕,胡腾,司果,等.尿激酶联合糖皮质激素胸腔注药治疗结核性胸膜炎的探讨[J].四川医学, 2010,31(11):1679-1680.
[15] 费立升,赵福泰,刘伟,等.尿激酶、氟美松预防结核性胸膜炎胸膜肥厚和包裹性积液[J].临床肺科杂志,2004,9(1):35-36.
[16] WANG J,XIAO L,CHEN J,et al.Potential effectiveness of traditional Chinese medicine for cardiac syndrome X (CSX):a systematic review and meta-analysis[J].BMC Complementary Alter Med,2013,13(1):62.
[17] TONG A,FLEMMING K,MCINNES E,et al.Enhancing transparency in reporting the synthesis of qualitative research:ENTREQ[J].BMC Med Res Methodol,2012,12:181.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录